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Introduction
Intracranial arterial stenosis is a frequent cause of major 
stroke [1]. Medical treatment with either platelet antiaggre-
gation or anticoagulation may be an option for asympto-
matic patients and for those not suitable for endovascular 
therapy. In patients with high-grade symptomatic stenoses, 
balloon dilatation using coronary stents [2], neurovascular 
variants thereof [3], or self-expanding stents [4] offers bet-
ter protection from stroke. In dedicated centers, these pro-
cedures are carried out safely and efficiently. The long-term 
course, however, remains a concern. The dilemma is that 
drug-eluting stents (des) provide good long-term results, 
but are just too stiff for elongated vessels. For all bare-metal 
stents (BMs), no matter if balloon-expandable, self-expan-
ding, stainless steel, cobalt-chromium or nickel-titanium, 
in-stent restenosis (Isr) rates of 30% and higher have been 
reported.
since Isr of > 50% lumen loss may again cause cerebral 
ischemia, treatment of these patients is mandatory. In the 
past, conventional balloon dilatation or the deployment of 
a second stent was established clinical practice. some years 
ago, scheller et al. could show in pigs that a short-term expo-
sure of the vessel wall to the antiproliferative drug paclitaxel 
is able to inhibit vascular smooth muscle cell proliferation 
for several days [5]. Angioplasty of coronary Isr perfor-
med with iopromide- and paclitaxel-coated balloons (drug-
eluting balloon [deB]) prevents restenosis more frequently 
and longer than the use of bare-surface balloons [6].
We report the clinical history of a young patient with a 
symptomatic,  presumably  inflammatory  proximal  middle 
cerebral artery (MCA) plaque, which was treated by bal-
loon dilatation and self-expanding stent deployment, follo-
wed by recurrent intracranial ISR. Three retreatments with 
conventional balloons were again followed by severe inti-
mal hyperplasia. After angioplasty with a deB, no further 
Isr occurred.
Case Report
An otherwise healthy 19-year-old woman presented with 
recurrent transient ischemic attacks. Medical history was 
free from any cerebrovascular risk factors or known heart 
disease. neurological signs and symptoms included episo-
des of right hemiparesis and aphasia. diffusion-weighted 
magnetic resonance imaging (dWI-MrI) showed several 
foci of restricted diffusion in the left MCA supply terri-
tory. digital subtraction angiography (dsA) on April 17, 
2008, revealed a high-grade stenosis in the proximal seg-
ment of the left M1 segment with residual flow (Fig. 1a). 
endovascular treatment with stent percutaneous translumi-
nal angioplasty (PTA) was planned for the next day and the 
patient received the standard dual platelet antiaggregation 
loading with 500 mg acetylsalicylic acid (AsA) and 600 mg   
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clopidogrel. one day later on April 18, the dsA examina-
tion under general anesthesia showed that the thrombus in 
the proximal M1 segment had resolved, leaving behind a 
plaque with vessel wall irregularity but without significant 
stenosis  (Fig. 1b).  endovascular  treatment  appeared  not 
necessary. only 3 days later on April 21, still under conti-
nued medication with 100 mg AsA and 75 mg clopidogrel 
daily, the proximal M1 segment was again narrow (Fig. 1c). 
We therefore decided to treat this lesion. The patient and 
her parents were informed about the diagnosis, the poten-
tial risks of the spontaneous course, and the treatment opti-
ons, including the off-label use of a coronary balloon and 
an aneurysm stent—and agreed upon. Under general anest-
hesia the distal segment of the left internal carotid artery 
(ICA) and the proximal M1 segment were dilated with a 
Ryujin Plus OTW balloon (Terumo; 2 mm/20 mm, 8 atm). 
A 4.5/14-mm enterprise stent (Codman) was deployed the-
reafter. The distal ICA and the proximal M1 vessel lumen 
were sufficiently dilated with a hemodynamically insignifi-
cant residual stenosis and a segmental narrowing of the left 
proximal A1 segment (Fig. 1d).
The  patient  continued  the  medication  with  ASA  and 
clopidogrel  and  remained  neurologically  asymptomatic 
thereafter. subsequent dsA examinations showed in-stent 
stenoses due to intimal hyperplasia, which were treated with 
conventional balloon dilatation as follows:
1.    first follow-up July 7, 2008, retreatment July 23, 2008: 
ryujin 2/20 mm, 10 atm, ∼ 2.12 mm (Fig. 2a and 2b);
2.    second  follow-up  september  3,  2008,  retreatment 
september  12,  2008:  ryujin  2 mm/20 mm,  10 atm, 
∼ 2.12 mm (Fig. 2c and 2d);
3.    third follow-up december 2, 2008, retreatment decem-
ber 8, 2008: ryujin 2.5 mm/10 mm, 8 atm, ∼ 2.58 mm 
(Fig. 2e and 2f).
since angiographic follow-up on January 21, 2009, again 
showed a significant ISR (Fig. 3a), angioplasty with a deB 
was proposed to the patient. All possible options, including 
further observation under increased medical antiaggrega-
tion, angioplasty with a conventional balloon, deployment 
of a BMs or des and temporal extra- to intracranial bypass 
surgery,  were  discussed  with  the  patient  and  her  family, 
including the related chances and risks and with explicit 
information about the off-label use aspects of some of these 
concepts. The patient finally opted for the retreatment with 
a deB, which was carried out on January 26, 2009. Under 
general anesthesia, a 0.014″ wire (X-celerator14, ev3) was 
inserted into the arteria gyri angularis of the left MCA with 
smooth passage of the Isr in the proximal M1 segment. pre-
dilatation (ryujin plus 1.5 mm/20 mm, 10 atm ∼ 1.61 mm) 
was  followed  by  angioplasty  using  the  paclitaxel-elu-
ting SeQuent Please balloon (B. Braun, Berlin, Germany; 
Fig. 1  Initial thrombus narro-
wing the left M1 segment (a). 
one day later under systemic 
heparinization and dual platelet 
inhibition, the thrombus was 
resolved and a long plaque 
extending from the distal ICA 
to the proximal MCA became 
visible (b). despite continued 
medication, dsA 3 days later 
again showed a critical vessel 
narrowing (c). Conventional 
balloon dilatation and deploy-
ment of an enterprise stent res-
tored the vessel diameter with 
some degree of residual stenosis 
of the distal ICA and the M1 
segment (d). The plaque itself 
remained visible. There was a 
preexisting high-grade stenosis 
of the proximal A1 segment, 
which remained untreated since 
the left ACA was supplied from 
both sides
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Fig. 2 Angiographic follow-up 
and three conventional retre-
atments. The three follow-up 
examinations were carried out 
77 days (a), 135 days (c), and 
225 days (e) after the initial 
treatment. each of the three 
conventional balloon angioplas-
ties was successful without any 
relevant residual stenoses (b, d, 
f). only 44 days after the third 
conventional balloon angioplas-
ty, the next Isr was found. In 
the meantime, the left proximal 
A1 segment was occluded 
without clinical sequels
Fig. 3  Isr of the left distal ICA and proximal MCA 275 days after ini-
tial stent PTA (Enterprise) and three conventional retreatments (a). The 
Isr was treated by gentle deB angioplasty (b). Further angiographic 
follow-up 273 days after deB treatment showed a widely patent and 
smooth vessel lumen (c)
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2 mm/20 mm, 10 atm ∼ 2.13 mm, 60 s inflation time). DSA 
after deB angioplasty showed a minimal residual stenosis 
(Fig. 3b). MrI after this treatment did not show new lesi-
ons.  Four  angiographic  follow-up  examinations,  the  last 
carried out on october 26, 2009, 273 days after the deB 
procedure, confirmed persistent patency of the stent without 
any further intimal hyperplasia or otherwise stenosis or ves-
sel wall abnormality. since the initial treatment, the patient 
had remained free from any ischemic symptoms.
Discussion
Intracranial stent PTA can now be performed with a high 
level of procedural safety and efficacy [4]. The “traditional” 
method using balloon-expandable stents is associated with 
an angiographic Isr rate > 30% [2]. The combination of 
undersized balloon dilatation followed by the deployment 
of a slightly oversized self-expanding stent allows access to 
the target vessel even in the case of very tortuous vessel ana-
tomy. The ISR rate, however, seems to be even higher, and 
these Isr are sometimes longer and tighter than the origi-
nal lesion. Furthermore, the rate of another recurrence after 
angioplasty of an Isr is about 50% [7].
Intracranial arterial stenoses do not represent a homoge-
neous vessel pathology. While atherosclerosis is certainly 
the most frequent cause, dissection and vasculitis may well 
result in narrowed arteries. From a theoretical standpoint, it 
can be difficult if not impossible to identify the underlying 
pathology in a given intracranial stenosis.
Inflammation is a major factor in the pathophysiology 
of recurrent stenosis and intimal hyperplasia [8]. In arterial 
stenoses due to vasculitis, the recurrence rate after stenting 
is way higher than in atherosclerosis [9]. This observation is 
in line with the fact that stenoses of the distal ICA in young 
patients  (sometimes  without  cerebrovascular  risk  factors 
and with no other atherosclerosis manifestations, insinua-
ting vasculitis) are notorious for Isr [10].
Isr is a frequently encountered phenomenon after stent 
treatment of coronary atherosclerosis. For a variety of indi-
cations, a reduced Isr rate after des deployment compa-
red to BMs results has been shown in coronary arteries [11, 
12]. delayed acute stent thrombosis is, however, one of the 
issues with des [13]. For intracranial indications, excellent 
follow-up results with des have been reported [14], inclu-
ding the treatment of Isr after BMs deployment [15]. As 
a major drawback, DES are significantly less flexible than 
BMs, leaving many intracranial arteries just unreachable.
In 2004, scheller et al. came up with the concept of a 
balloon catheter as a drug carrier [5]. on the surface of an 
otherwise regular balloon, the antiproliferative drug paclita-
xel is fixated. Iopromide is used as an “enhancer”. During 
balloon insertion, only minimal amounts of the drug are lost 
in the blood stream. The drug itself is brought in close con-
tact with the luminal surface of the vessel intima by balloon 
inflation. Within 60 s of balloon inflation, about 16% of the 
available substance (3 µg/mm2) are taken up by the adja-
cent intima. Within the smooth muscle cells, paclitaxel is a 
potent antiproliferative agent that inhibits cell division and 
migration by formation of abnormally stable microtubules 
[16]. This inhibition of intimal cell proliferation may last 
weeks and even months.
The combination of mechanical balloon dilatation and 
local drug application was confirmed to be very efficient for 
the treatment of coronary Isr [6]. Little is known if the same 
is true for intracranial recurrent stenoses. It may be argued 
that the risk of losing the paclitaxel coating of the balloon 
may be higher in intracranial vessels due to the tight vessel 
curves, which was apparently not the case in the successful 
treatment of the patient reported here. In the presented case, 
Isr could have been a self-limiting process, and the deB 
was incidentally used when the power of the underlying 
pathology was already exhausted spontaneously. Follow-
up results after redilatation of intracranial arterial stenoses 
have not been reported on a large-scale basis. We therefore 
have no comparative data available for conventional bal-
loons. A randomized trial for the comparison of conventio-
nal balloons and deB for the treatment of intracranial Isr 
would probably need a long time to get a sufficient number 
of cases enrolled. paclitaxel has been shown to be effective 
in ISR in cardiologic patients. Their underlying disease is 
atherosclerosis. In the young female patient reported here, it 
is very likely that the etiology is not atherosclerosis, but the 
use of paclitaxel is still effective.
The DEB SeQuent Please is not optimized for intracranial 
vessels. For older patients with elongated vessels, an “over-
the-wire” variant with a reduced crossing profile and a softer 
catheter tip would allow better access to the target lesion. 
stimulated by the clinical success of the seQuent please, 
several competing products became available. They deli-
ver antiproliferative drugs, but due to intellectual property 
reasons they come without or with another “enhancer” that 
both fixates the active substance on the balloon surface and 
facilitates the deposition of paclitaxel in the intimal cells.
Conclusion
Anecdotal experience shows that deB angioplasty can be 
a safe and efficient treatment for intracranial ISR. Larger 
series and, eventually, a randomized trial have to compare 
conventional versus DEB dilatation. The primary use of a 
DEB, optimized for intracranial vessels and followed by the 
deployment of a self-expanding stent, might be a way to 
overcome the currently high rate of Isr after intracranial 
stenting and PTA.169 recurrent In-stent restenosis in a symptomatic nonatherosclerotic M1 plaque
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